ACTRN12612001272886已完成3 期
A phase three open label Randomized Controlled Trial to compare the efficacy of oral anti-diabetic drugs with insulin in the treatment of GDM
Dr Aisha Syed Wali0 个研究点目标入组 154 人开始时间: 2012年12月7日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 154
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- Female
入选标准
- •Women diagnosed as GDM, according to criteria given in the protocol.
- •Singleton pregnancy.
- •Women who consented for study.
排除标准
- •Pre-gestational type 1 and type 2 diabetes mellitus
- •Overt diabetes (FBG > or equal to 126 mg/dl, Hb A1C > or equal to 6.5%)
- •Gestational age > 33 weeks at the time of recruitment.
- •Patients on steroid therapy
- •Women not tolerating Oral Glucose Tolerance Test.
研究者
相似试验
尚未招募
3 期
Randomized Controlled Trial Of Resveretrol-Copper Or Sodium-Copper-Chlorophyllin Vs Standard Treatment In Mild Covid-19 infectioCTRI/2020/05/025336Tata Memorial Centre
尚未招募
3 期
Randomized Controlled Trial Of Resveretrol-Copper Or Sodium-Copper-Chlorophyllin Vs Standard Treatment In Mild Covid-19 infection with Cancer Patients.CTRI/2020/07/026515Tata Memorial Centre
已完成
3 期
Phase III Controlled Trial of gMSC1 in Patients with Symptomatic Articular Cartilage Defects or Osteochondritis Dissecans in the KneeJPRN-jRCT1080223548TWOCELLS COMPANY, LIMITED70
尚未招募
3 期
A study to find which drug (metoclopramide, thalidomide, prochlorperazine, or lorazepam) is best to treat vomiting due to chemotherapy in patients with cancer.CTRI/2024/08/072429Cancer Institute WIA
招募中
1 期
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)C-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104CTIS2023-505749-14-00AbbVie Deutschland GmbH & Co. KG702